<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LUP</journal-id>
<journal-id journal-id-type="hwp">splup</journal-id>
<journal-id journal-id-type="nlm-ta">Lupus</journal-id>
<journal-title>Lupus</journal-title>
<issn pub-type="ppub">0961-2033</issn>
<issn pub-type="epub">1477-0962</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0961203312462756</article-id>
<article-id pub-id-type="publisher-id">10.1177_0961203312462756</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Free fatty acids are associated with metabolic syndrome and insulin resistance but not inflammation in systemic lupus erythematosus</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Ormseth</surname><given-names>MJ</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312462756">1</xref>
<xref ref-type="corresp" rid="corresp1-0961203312462756"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Swift</surname><given-names>LL</given-names></name>
<xref ref-type="aff" rid="aff2-0961203312462756">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Fazio</surname><given-names>S</given-names></name>
<xref ref-type="aff" rid="aff3-0961203312462756">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Linton</surname><given-names>MF</given-names></name>
<xref ref-type="aff" rid="aff3-0961203312462756">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Raggi</surname><given-names>P</given-names></name>
<xref ref-type="aff" rid="aff4-0961203312462756">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Solus</surname><given-names>JF</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312462756">1</xref>
<xref ref-type="aff" rid="aff5-0961203312462756">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Oeser</surname><given-names>A</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312462756">1</xref>
<xref ref-type="aff" rid="aff6-0961203312462756">6</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Bian</surname><given-names>A</given-names></name>
<xref ref-type="aff" rid="aff7-0961203312462756">7</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Gebretsadik</surname><given-names>T</given-names></name>
<xref ref-type="aff" rid="aff7-0961203312462756">7</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Shintani</surname><given-names>A</given-names></name>
<xref ref-type="aff" rid="aff7-0961203312462756">7</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Stein</surname><given-names>CM</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312462756">1</xref>
<xref ref-type="aff" rid="aff6-0961203312462756">6</xref>
</contrib>
</contrib-group>
<aff id="aff1-0961203312462756"><label>1</label>Division of Rheumatology, Department of Medicine, Vanderbilt University, USA</aff>
<aff id="aff2-0961203312462756"><label>2</label>Department of Pathology, Microbiology, and Immunology, School of Medicine, Vanderbilt University, USA</aff>
<aff id="aff3-0961203312462756"><label>3</label>Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University, USA</aff>
<aff id="aff4-0961203312462756"><label>4</label>Division of Cardiology, Department of Medicine, Emory University, USA</aff>
<aff id="aff5-0961203312462756"><label>5</label>Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University, USA</aff>
<aff id="aff6-0961203312462756"><label>6</label>Division of Clinical Pharmacology, Department of Pharmacology, Vanderbilt University, USA</aff>
<aff id="aff7-0961203312462756"><label>7</label>Department of Biostatistics, School of Medicine, Vanderbilt University, USA</aff>
<author-notes>
<corresp id="corresp1-0961203312462756">Correspondence to: Michelle J Ormseth, Division of Rheumatology, Department of Medicine, Vanderbilt University, 1161 21st Avenue South, T-3219 MCN, Nashville, TN 37232-2681, USA. Email: <email>michelle.ormseth@vanderbilt.edu</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>1</month>
<year>2013</year>
</pub-date>
<volume>22</volume>
<issue>1</issue>
<fpage>26</fpage>
<lpage>33</lpage>
<history>
<date date-type="received"><day>27</day><month>2</month><year>2012</year></date>
<date date-type="accepted"><day>28</day><month>8</month><year>2012</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s), 2012. Reprints and permissions: http://www.sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Free fatty acids (FFAs) are implicated in the pathogenesis of insulin resistance and atherosclerosis. Inflammatory cytokines promote lipolysis and increase FFAs, a cause of endothelial dysfunction and increased atherosclerosis risk. We hypothesized that increased inflammation is associated with increased FFAs, resulting in insulin resistance and atherosclerosis in patients with systemic lupus erythematosus (SLE). We measured clinical variables, serum FFAs, homeostasis model assessment for insulin resistance (HOMA), inflammatory cytokines, markers of endothelial activation, cholesterol concentrations and coronary artery calcium in 156 patients with SLE and 90 controls. We compared FFAs in patients with SLE and controls using Wilcoxon rank sum tests and further tested for the independent association between FFAs and disease status with adjustment for age, race and sex using multivariable regression models. We assessed the relationship between FFAs and continuous variables of interest using Spearman correlation and multivariable regression analysis. Levels of FFAs were higher in patients with SLE than controls (0.55 mmol/l (0.37–0.71) vs 0.44 mmol/l (0.32–0.60), <italic>P = </italic>0.02). Levels of FFAs remained significantly higher among patients with SLE after adjustment for age, race and sex (<italic>P = </italic>0.03) but not after further adjustment for body mass index (<italic>P = </italic>0.13). FFA levels did not differ according to the usage of current immunosuppressive medications in univariate and adjusted analysis (all <italic>P &gt; </italic>0.05). Among patients with SLE, concentrations of FFAs were higher among those with metabolic syndrome compared to those without (0.66 mmol/l (0.46–0.81) vs 0.52 mmol/l (0.35–0.66), <italic>P &lt; </italic>0.001). FFAs were positively correlated with insulin resistance (HOMA) (rho = 0.23, <italic>P = </italic>0.004, <italic>P</italic> adjusted = 0.006) and triglyceride levels (rho = 0.22, <italic>P = </italic>0.01, <italic>P</italic> adjusted = 0.004). FFAs were not associated with inflammatory cytokines (IL-6, TNF-α) (all <italic>P &gt; </italic>0.05) but were positively associated with levels of E-selectin (rho = 0.33, <italic>P =</italic> &lt; 0.001, <italic>P</italic> adjusted = 0.001) and ICAM-1 (rho = 0.35, <italic>P &lt; </italic>0.001, <italic>P</italic> adjusted = 0.001). FFAs were correlated with coronary artery calcium score (rho = 0.20, <italic>P = </italic>0.01) but this was attenuated after adjustment for age, race and sex (<italic>P = </italic>0.33). From our study we concluded that FFAs are elevated in patients with SLE, particularly those with metabolic syndrome. FFAs in patients with SLE are not associated with markers of generalized inflammation but are associated with insulin resistance and markers of endothelial activation</p>
</abstract>
<kwd-group>
<kwd>Cardiovascular disease</kwd>
<kwd>systemic lupus erythematosus</kwd>
<kwd>free fatty acids</kwd>
<kwd>metabolic syndrome</kwd>
<kwd>endothelial activation</kwd>
<kwd>insulin resistance</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0961203312462756" sec-type="intro"><title>Introduction</title>
<p>Patients with systemic lupus erythematosus (SLE) have an increased prevalence of premature atherosclerosis even after adjusting for traditional cardiovascular risk factors.<sup><xref ref-type="bibr" rid="bibr1-0961203312462756">1</xref>–<xref ref-type="bibr" rid="bibr4-0961203312462756">4</xref></sup> We have previously reported that patients with SLE frequently meet criteria for metabolic syndrome and have a high prevalence of insulin resistance.<sup><xref ref-type="bibr" rid="bibr5-0961203312462756">5</xref></sup></p>
<p>Insulin resistance and metabolic syndrome are associated with increased cardiovascular mortality in the general population<sup><xref ref-type="bibr" rid="bibr6-0961203312462756">6</xref></sup> but the underlying mechanisms are unclear. The relationship between obesity, increased inflammation, insulin resistance and cardiovascular disease may be explained by free fatty acids (FFAs).<sup><xref ref-type="bibr" rid="bibr7-0961203312462756">7</xref></sup></p>
<p>FFAs are released from adipocytes through lipolysis and are elevated in obesity due to increased adipose tissue.<sup><xref ref-type="bibr" rid="bibr8-0961203312462756">8</xref></sup> Insulin can down-regulate lipolysis but where there is insulin resistance this regulatory mechanism is impaired, resulting in increased plasma FFAs.<sup><xref ref-type="bibr" rid="bibr9-0961203312462756">9</xref>–<xref ref-type="bibr" rid="bibr11-0961203312462756">11</xref></sup> In addition, elevated FFAs also promote peripheral insulin resistance leading to the release of more FFAs because the anti-lipolytic action of insulin is impaired.<sup><xref ref-type="bibr" rid="bibr12-0961203312462756">12</xref></sup></p>
<p>Inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α) stimulate lipolysis and increase FFAs.<sup><xref ref-type="bibr" rid="bibr13-0961203312462756">13</xref>,<xref ref-type="bibr" rid="bibr14-0961203312462756">14</xref></sup> However, an experimental study with rats showed acutely-induced elevation of FFAs increases hepatic expression of IL-6 and TNF-α.<sup><xref ref-type="bibr" rid="bibr15-0961203312462756">15</xref></sup> Similarly, in healthy humans an acute increase in FFAs induces oxidative stress and inflammatory changes.<sup><xref ref-type="bibr" rid="bibr16-0961203312462756">16</xref></sup> Therefore, FFAs not only promote inflammation but are also increased by inflammation.</p>
<p>Elevated FFAs result in increased concentrations of soluble endothelial activation markers including E-selectin, vascular cellular adhesion molecule 1 (VCAM-1) and intracellular adhesion molecule 1 (ICAM-1).<sup><xref ref-type="bibr" rid="bibr17-0961203312462756">17</xref></sup> Furthermore, FFAs can decrease endothelial nitric oxide production and increase reactive oxygen species,<sup><xref ref-type="bibr" rid="bibr18-0961203312462756">18</xref></sup> predisposing to endothelial dysfunction,<sup><xref ref-type="bibr" rid="bibr19-0961203312462756">19</xref></sup> a potential mechanism underlying atherosclerosis and coronary artery disease.<sup><xref ref-type="bibr" rid="bibr20-0961203312462756">20</xref></sup></p>
<p>Patients with SLE have chronic inflammation and an increased prevalence of insulin resistance, endothelial dysfunction and coronary atherosclerosis. However, little is known about the contribution of FFAs to the development of these conditions. We therefore put forward the hypothesis that a unifying mechanism underlying accelerated atherosclerosis in SLE is that inflammation increases FFAs resulting in insulin resistance and atherosclerosis.</p>
</sec>
<sec id="sec2-0961203312462756" sec-type="materials|methods"><title>Materials and methods</title>
<sec id="sec3-0961203312462756"><title>Study population</title>
<p>We studied 156 patients with SLE without diagnosed coronary artery disease and 90 control subjects in whom serum FFAs were measured. These patients were from a larger cohort of patients in which the relationship between inflammation and atherosclerosis have been well defined.<sup><xref ref-type="bibr" rid="bibr1-0961203312462756">1</xref>,<xref ref-type="bibr" rid="bibr4-0961203312462756">4</xref>,<xref ref-type="bibr" rid="bibr5-0961203312462756">5</xref>,<xref ref-type="bibr" rid="bibr21-0961203312462756">21</xref>,<xref ref-type="bibr" rid="bibr22-0961203312462756">22</xref></sup> Recruitment and study procedures have been described in detail.<sup><xref ref-type="bibr" rid="bibr1-0961203312462756">1</xref></sup> Subjects were 18 years of age or older and patients with SLE fulfilled the 1982 classification criteria.<sup><xref ref-type="bibr" rid="bibr23-0961203312462756">23</xref></sup> Control subjects did not have SLE or any other inflammatory disease. The patient and control groups were frequency-matched for age, race and sex. The study was approved by the Vanderbilt University Institutional Review Board and all subjects gave written informed consent.</p>
</sec>
<sec id="sec4-0961203312462756"><title>Clinical data</title>
<p>Clinical information, laboratory data and coronary calcium scores were obtained as described previously.<sup><xref ref-type="bibr" rid="bibr1-0961203312462756">1</xref>,<xref ref-type="bibr" rid="bibr4-0961203312462756">4</xref>,<xref ref-type="bibr" rid="bibr5-0961203312462756">5</xref></sup> Disease activity and damage were evaluated with the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)<sup><xref ref-type="bibr" rid="bibr24-0961203312462756">24</xref></sup> and the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index (SLICC), respectively.<sup><xref ref-type="bibr" rid="bibr25-0961203312462756">25</xref></sup> The Framingham risk score was calculated using blood pressure, smoking status, serum lipid concentrations, age and sex but not diabetes.<sup><xref ref-type="bibr" rid="bibr26-0961203312462756">26</xref></sup> Body mass index (BMI) was calculated and expressed as kg/m<sup>2</sup>. Insulin resistance was measured using the homeostasis model assessment of insulin resistance (HOMA) index and calculated as (serum insulin (μU/ml) × glucose (mmol/l))/ 22.5.<sup><xref ref-type="bibr" rid="bibr27-0961203312462756">27</xref></sup></p>
<p>The modified World Health Organization Criteria was used to classify a patient as having metabolic syndrome, which requires the presence of insulin resistance defined by any of the following criteria: HOMA in the top quartile of a population without diabetes, impaired fasting glucose (≥110 mg/dl) or diabetes. In addition, two of the following three criteria are also required: (1) central obesity: waist &gt;94  cm in men and &gt;88 cm in women; (2) dyslipidemia: triglycerides ≥150 mg/dl, or high density lipoprotein (HDL) &lt;40 mg/dl in women or &lt;35 mg/dl in men; and (3) high blood pressure: ≥140/90 mmHg or use of drugs for hypertension.<sup><xref ref-type="bibr" rid="bibr28-0961203312462756">28</xref></sup> Based on the Study of Inherited Risk of Coronary Atherosclerosis data we defined a HOMA index &gt;2.114 as representing the top quartile of a population without diabetes.<sup><xref ref-type="bibr" rid="bibr29-0961203312462756">29</xref></sup></p>
<p>FFAs were measured using an enzymatic assay (HR series NEFA-HR(2) assay, Wako Diagnostics, Richmond, VA, USA) from serum samples obtained after an overnight fast and expressed as mmol/L. The expected normal range for serum FFAs for fasting patients is 0.1–0.6 mmol/L. The range of linearity of this method is up to 2.0 mmol/L. The inter-assay coefficient of variation is 2.7% for levels in the normal range and 1.1% for elevated levels. Glucose, total cholesterol, triglycerides, HDL and low density lipoprotein (LDL) were measured by the Vanderbilt University Medical Center Clinical Laboratory. IL-6, TNF-α, insulin, soluble E-selectin, VCAM-1 and ICAM-1 were measured by multiplex ELISA (Lincoplex® Multiplex Immunoassay Kit, Millipore Corp., Billerica, MA, USA) in 115 patients with SLE and 83 controls.</p>
<p>Coronary artery calcium was measured by electron beam computed tomography (EBCT) scanning with an Imatron C-150 scanner (GE/Imatron, South San Francisco, CA, USA) in 108 patients with SLE and 80 controls, and a 64-row multidector CT (Light-Speed VCT, General Electric, Waukesha, WI, USA) in 29 patients with SLE and five controls. Coronary artery calcium scores were quantified in Agatston units.<sup><xref ref-type="bibr" rid="bibr29-0961203312462756">29</xref></sup> Scans were not performed in 18 patients with SLE and five control patients for logistical reasons.</p>
</sec>
<sec id="sec5-0961203312462756"><title>Statistical analysis</title>
<p>Descriptive statistics were calculated as median with the interquartile range (median (IQR)) for continuous variables, and frequency and proportion for categorical variables. Wilcoxon’s rank sum tests were used to compare continuous variables between patients with SLE and control subjects, and Pearson’s chi-square test was used to compare categorical variables. We first assessed for the independent association of FFAs and disease status by adjusting for age, sex and race, and second in a separate model, with further adjustment for BMI.</p>
<p>To assess the correlation between FFAs and continuous clinical variables (including the coronary artery calcium score), Spearman’s rank correlation coefficients (rho) were calculated separately among patients with SLE and control subjects.</p>
<p>The independent associations between FFAs and components of the lipid profile (total cholesterol, LDL, HDL and triglycerides), markers of insulin resistance (HOMA, fasting glucose and insulin), inflammation (IL-6, TNF-α), markers of endothelial activation (E-selectin, ICAM-I and VCAM-I), Framingham risk score, current use of medications and SLE disease activity (SLEDAI and SLICC) were assessed using multivariable linear regression models with adjustment for age, race and sex.</p>
<p>In addition, we tested whether the association of FFAs with HOMA and metabolic syndrome were independent of BMI by further including BMI to the above model.</p>
<p>Similar regression analysis was performed for markers of endothelial activation. To assess the association between FFAs and markers of endothelial activation (E-selectin, ICAM-1 and VCAM-1) independent of inflammation, we further adjusted for IL-6 and TNF-α separately.</p>
<p>The association between FFAs and coronary artery calcium score was examined with a proportional odds logistic regression model adjusting for age, race and sex.</p>
<p>Concentrations of FFAs, triglycerides, HOMA, VCAM-1, ICAM-1, E-selectin, IL-6 and TNF-α were natural logarithm-transformed to improve normality. Statistical analyses were performed using R version 2.10.0 (http://www.r-project.org) and two-sided <italic>P</italic> values less than 0.05 were considered statistically significant.</p>
</sec>
</sec>
<sec id="sec6-0961203312462756" sec-type="results"><title>Results</title>
<sec id="sec7-0961203312462756"><title>Demographics</title>
<p>Demographic, clinical and laboratory characteristics of patients with SLE and control subjects have been reported previously (<xref ref-type="table" rid="table1-0961203312462756">Table 1</xref>).<sup><xref ref-type="bibr" rid="bibr1-0961203312462756">1</xref>,</sup> <sup><xref ref-type="bibr" rid="bibr4-0961203312462756">4</xref>,<xref ref-type="bibr" rid="bibr5-0961203312462756">5</xref></sup> Patient and control groups were similar with regard to age (40 years (30–48) vs 42 years (30–49), <italic>P = </italic>0.72), sex (12% vs 13% male, <italic>P = </italic>0.68), and race (67% vs 73% Caucasian, <italic>P = </italic>0.32). However, BMI (27.3 kg/m<sup>2</sup> (23.4–32.7) vs 25.2 kg/m<sup>2</sup> (22.5–30.1), <italic>P = </italic>0.04), as well as the prevalence of the metabolic syndrome (25.6% vs 8.9%, <italic>P = </italic>0.001), was higher in patients with SLE.
<table-wrap id="table1-0961203312462756" position="float"><label>Table 1</label><caption><p>Characteristics of patients with systemic lupus erythematosus and control subjects</p></caption>
<graphic alternate-form-of="table1-0961203312462756" xlink:href="10.1177_0961203312462756-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th/>
<th>SLE <italic>n =</italic> 156</th>
<th>Controls <italic>n =</italic> 90</th>
<th><italic>P</italic> value</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Age (years)</td>
<td>40 [30–48]</td>
<td>42 [30–49]</td>
<td>0.72</td>
</tr>
<tr>
<td>Sex (% male)</td>
<td>12%</td>
<td>13%</td>
<td>0.68</td>
</tr>
<tr>
<td>Race (% Caucasian)</td>
<td>67%</td>
<td>73%</td>
<td>0.32</td>
</tr>
<tr>
<td>BMI (kg/m<sup>2</sup>)</td>
<td>27.3 [23.4–32.7]</td>
<td>25.2 [22.5–30.1]</td>
<td>0.04</td>
</tr>
<tr>
<td>Current smoker</td>
<td>21%</td>
<td>18%</td>
<td>0.60</td>
</tr>
<tr>
<td>Hypertension</td>
<td>43%</td>
<td>17%</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Systolic BP (mmHg)</td>
<td>116 [106–127]</td>
<td>116 [107–127]</td>
<td>0.85</td>
</tr>
<tr>
<td>Diastolic BP (mmHg)</td>
<td>72 [65–79]</td>
<td>70 [64–78]</td>
<td>0.40</td>
</tr>
<tr>
<td>Diabetes</td>
<td>3.9%</td>
<td>1.1%</td>
<td>0.21</td>
</tr>
<tr>
<td>Metabolic syndrome</td>
<td>25.6%</td>
<td>8.9%</td>
<td>0.001</td>
</tr>
<tr>
<td>HOMA</td>
<td>1.47 [0.69–2.52]</td>
<td>1.08 [0.66–2.08]</td>
<td>0.085</td>
</tr>
<tr>
<td>Fasting glucose (mg/dl)</td>
<td>82 [76–91]</td>
<td>84.5 [80–89.8]</td>
<td>0.12</td>
</tr>
<tr>
<td>Waist hip ratio<sup><xref ref-type="table-fn" rid="table-fn3-0961203312462756">a</xref></sup></td>
<td>0.846 [0.787–0.908]</td>
<td>0.805 [0.75–0.866]</td>
<td>0.003</td>
</tr>
<tr>
<td>Statin use</td>
<td>12.8%</td>
<td>7.8%</td>
<td>0.22</td>
</tr>
<tr>
<td>Total cholesterol (mg/dl)</td>
<td>166 [139–203]</td>
<td>181 [160–205]</td>
<td>0.04</td>
</tr>
<tr>
<td>HDL cholesterol (mg/dl)</td>
<td>48 [36–55]</td>
<td>47 [38–61]</td>
<td>0.47</td>
</tr>
<tr>
<td>LDL cholesterol (mg/dl)</td>
<td>94 [76–125]</td>
<td>110 [89–134]</td>
<td>0.004</td>
</tr>
<tr>
<td>Triglycerides (mg/dl)</td>
<td>104 [76–149]</td>
<td>82 [63–117]</td>
<td>0.002</td>
</tr>
<tr>
<td>IL-6 (pg/ml)<sup><xref ref-type="table-fn" rid="table-fn4-0961203312462756">b</xref></sup></td>
<td>5.83 [2.27–26.81]</td>
<td>1.77 [0.87–4.73]</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>TNF-α (pg/ml)<sup><xref ref-type="table-fn" rid="table-fn5-0961203312462756">c</xref></sup></td>
<td>4.8 [3.0–8.0]</td>
<td>2.4 [1.8–3.0]</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>E-selectin (ng/ml)<sup><xref ref-type="table-fn" rid="table-fn5-0961203312462756">c</xref></sup></td>
<td>23.9 [17.7–28.6]</td>
<td>18.4 [13.8–23.0]</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>ICAM-1 (ng/ml)<sup><xref ref-type="table-fn" rid="table-fn5-0961203312462756">c</xref></sup></td>
<td>175.9 [135.5–226.5]</td>
<td>142.9 [118.2–176.0]</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>VCAM-1 (ng/ml)<sup><xref ref-type="table-fn" rid="table-fn5-0961203312462756">c</xref></sup></td>
<td>1,077.4 [887.9–1203.3]</td>
<td>984.4 [810.2–1105.4]</td>
<td>0.04</td>
</tr>
<tr>
<td>Disease duration (years)</td>
<td>6 [3–11]</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>SLEDAI</td>
<td>4 [0–6]</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>SLICC</td>
<td>1 [0–1]</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Framingham risk score</td>
<td>5 [1–10]</td>
<td>7 [0–11]</td>
<td>0.77</td>
</tr>
<tr>
<td>CAC (Agatston units)<sup><xref ref-type="table-fn" rid="table-fn6-0961203312462756">d</xref></sup>,*</td>
<td>0.0 [0.0–0.0] (66.7 ± 340.0)</td>
<td>0.0 [0.0–0.0] (3.5±26.5)</td>
<td>0.002</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0961203312462756"><p>BMI: body mass index; BP: blood pressure; HOMA: homeostasis model assessment of insulin resistance; IL-6: interleukin 6; TNFα: tumor necrosis factor-α; ICAM-1; intracellular adhesion molecule 1; VCAM-1: vascular cell adhesion molecule 1; SLE: systemic lupus erythematosus; SLEDAI: Systemic Lupus Erythematosus Disease Activity Index; SLICC: Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index; CAC: Agatston coronary artery calcium score.</p></fn>
<fn id="table-fn2-0961203312462756"><p>Note: Data presented as median [interquartile range] or percentage (%). *For CAC, data is also presented as (mean ± SD). <italic>P</italic> values for Wilcoxon rank sum test for continuous variables and Pearson’s chi-square test for categorical variables.</p></fn>
<fn id="table-fn3-0961203312462756"><label>a</label><p>Data available for <italic>n =</italic> 224.</p></fn>
<fn id="table-fn4-0961203312462756"><label>b</label><p>Data available for <italic>n =</italic> 186.</p></fn>
<fn id="table-fn5-0961203312462756"><label>c</label><p>Data available for <italic>n =</italic> 192.</p></fn>
<fn id="table-fn6-0961203312462756"><label>d</label><p>Data available for <italic>n =</italic> 238.</p></fn></table-wrap-foot>
</table-wrap></p>
</sec>
<sec id="sec8-0961203312462756"><title>Association of FFAs with SLE status and inflammation</title>
<p>Concentrations of FFAs in patients with SLE were higher than in controls (0.55 mmol/L (0.37–0.71) vs 0.44 mmol/L (0.32–.60), <italic>P = </italic>0.02) (<xref ref-type="fig" rid="fig1-0961203312462756">Figure 1</xref>); this remained significant after adjustment for age, race and sex (<italic>P = </italic>0.03). FFAs were positively correlated with BMI in patients with SLE (rho = 0.35, <italic>P &lt; </italic>0.001) so further adjustment was made for BMI and the association between FFA and SLE status was no longer significant (<italic>P = </italic>0.13).
<fig id="fig1-0961203312462756" position="float"><label>Figure 1</label><caption><p>Free fatty acids (mmol/L) in patients with SLE and Control subjects.</p>
<p>FFAs were higher in SLE than controls (0.55 mmol/L [0.37-0.71) vs 0.44 mmol/L [0.32-0.60], P = 0.02). This remained significant after adjustment for age, race and sex (P adjusted = 0.03), but not after additional adjustment for BMI (P adjusted = 0.13). Data are presented as box plot where boxes represent the interquartile range [IQR], the lines within boxes represent the median, and the lines outside the boxes represent the lower quartile minus 1.5 times the IQR or the upper quartile plus 1.5 times the IQR.</p></caption><graphic xlink:href="10.1177_0961203312462756-fig1.tif"/>
</fig></p>
<p>Among patients with SLE there was no association between FFAs and the inflammatory mediators, IL-6 or TNF-α (<xref ref-type="table" rid="table2-0961203312462756">Table 2</xref>), both in univariate or adjusted analysis. There was a trend towards an inverse association between FFAs and SLEDAI, a measure of disease activity in univariate analysis (rho = −0.19, <italic>P = </italic>0.02, <italic>P</italic> adjusted = 0.08) but not between FFAs and SLICC, a measure of disease damage (rho = 0.01, <italic>P = </italic>0.88, <italic>P</italic> adjusted = 0.47) (<xref ref-type="table" rid="table2-0961203312462756">Table 2</xref>).
<table-wrap id="table2-0961203312462756" position="float"><label>Table 2</label><caption><p>Correlation between free fatty acids and measures of inflammation, insulin resistance and coronary atherosclerosis in systemic lupus erythematosus</p></caption>
<graphic alternate-form-of="table2-0961203312462756" xlink:href="10.1177_0961203312462756-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th/>
<th>Rho<sup><xref ref-type="table-fn" rid="table-fn8-0961203312462756">a</xref></sup></th>
<th><italic>P</italic> value</th>
<th>Adjusted<sup><xref ref-type="table-fn" rid="table-fn9-0961203312462756">b</xref></sup> <italic>P</italic> value</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Lipids</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> Total cholesterol</td>
<td>0.11</td>
<td>0.16</td>
<td>0.47</td>
</tr>
<tr>
<td> LDL cholesterol</td>
<td>0.08</td>
<td>0.31</td>
<td>0.55</td>
</tr>
<tr>
<td> HDL cholesterol</td>
<td>−0.07</td>
<td>0.41</td>
<td>0.06</td>
</tr>
<tr>
<td> Triglycerides</td>
<td>0.22</td>
<td>0.005*</td>
<td>0.004*</td>
</tr>
<tr>
<td>Insulin resistance</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> HOMA</td>
<td>0.23</td>
<td>0.004*</td>
<td>0.006*</td>
</tr>
<tr>
<td>Inflammatory markers</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> IL-6</td>
<td>0.06</td>
<td>0.54</td>
<td>0.31</td>
</tr>
<tr>
<td> TNFα</td>
<td>−0.002</td>
<td>0.98</td>
<td>0.46</td>
</tr>
<tr>
<td>Endothelial activation</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> E-selectin</td>
<td>0.33</td>
<td>&lt;0.001*</td>
<td>0.001*</td>
</tr>
<tr>
<td> VCAM-1</td>
<td>0.02</td>
<td>0.80</td>
<td>0.61</td>
</tr>
<tr>
<td> ICAM-1</td>
<td>0.35</td>
<td>&lt;0.001*</td>
<td>0.001*</td>
</tr>
<tr>
<td>Coronary artery disease</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> FRS</td>
<td>0.25</td>
<td>0.002*</td>
<td>0.25</td>
</tr>
<tr>
<td> CAC</td>
<td>0.20</td>
<td>0.01*</td>
<td>0.33<sup><xref ref-type="table-fn" rid="table-fn10-0961203312462756">c</xref></sup></td>
</tr>
<tr>
<td>Other</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> BMI</td>
<td>0.35</td>
<td>&lt;0.001*</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td> SLEDAI</td>
<td>−0.19</td>
<td>0.02*</td>
<td>0.08</td>
</tr>
<tr>
<td> SLICC</td>
<td>0.01</td>
<td>0.88</td>
<td>0.47</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn7-0961203312462756"><p>HOMA: homeostasis model assessment of insulin resistance; IL-6: interleukin 6; TNFα: tumor necrosis factor-α; VCAM-1: vascular cell adhesion molecule 1; ICAM-1: intracellular adhesion molecule 1; FRS: Framingham risk score; CAC: Agatston coronary artery calcium score; BMI: body mass index; SLEDAI: Systemic Lupus Erythematosus Disease Activity Index; SLICC: Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index.</p></fn>
<fn id="table-fn8-0961203312462756"><label>a</label><p>Spearman’s correlation coefficient.</p></fn>
<fn id="table-fn9-0961203312462756"><label>b</label><p>Multivariable linear regression model with adjustment for age, race and sex.</p></fn>
<fn id="table-fn10-0961203312462756"><label>c</label><p>Proportional logistic regression model with adjustment for age, race and sex. *<italic>P &lt;</italic> 0.05.</p></fn></table-wrap-foot>
</table-wrap></p>
</sec>
<sec id="sec9-0961203312462756"><title>Association of FFAs with insulin resistance and metabolic syndrome</title>
<p>In patients with SLE, FFAs were positively correlated with HOMA (rho = 0.23, <italic>P = </italic>0.004) (<xref ref-type="table" rid="table2-0961203312462756">Table 2</xref>). FFAs were higher in those with metabolic syndrome compared to those without (0.66 mmol/L (0.46–0.81) vs 0.52 mmol/L (0.35–0.66), <italic>P &lt; </italic>0.001) (<xref ref-type="fig" rid="fig2-0961203312462756">Figure 2</xref>). These associations remained significant after adjustment for age, race and sex (<italic>P = </italic>0.006 for HOMA, <italic>P = </italic>0.002 for metabolic syndrome) but were attenuated after further adjustment for BMI (<italic>P = </italic>0.40 for HOMA, <italic>P = </italic>0.11 for metabolic syndrome). FFAs were associated with triglycerides (rho = 0.22, <italic>P = </italic>0.005, <italic>P</italic> adjusted = 0.004).
<fig id="fig2-0961203312462756" position="float"><label>Figure 2</label><caption><p>Free fatty acids concentrations (mmol/L) in SLE patients without (No) and with (Yes) metabolic syndrome as defined by WHO criteria.</p>
<p>FFAs were higher in those with metabolic syndrome compared to those without (0.66 mmol/L [0.46-0.81] vs. 0.52 mmol/L [0.35-0.66]), P &lt; 0.001). This remained significant after adjustment for age, race and sex (adjusted P = 0.002), but not after additional adjustment for BMI (adjusted P = 0.11). Data arepresent as box plot where boxes represent the interquartile range [IQR], the line within boxes represnt the median, and the lines outside the boxes represent the lower quartile minus 1.5 times the IQR or the upper quartile plus 1.5 times the IQR.</p></caption><graphic xlink:href="10.1177_0961203312462756-fig2.tif"/>
</fig></p>
</sec>
<sec id="sec10-0961203312462756"><title>Association of FFAs with cardiovascular risk and endothelial activation</title>
<p>FFAs were positively correlated with cardiovascular risk as determined by the Framingham risk score (rho = 0.25, <italic>P = </italic>0.002) and with coronary artery calcium score in univariate analysis (rho = 0.20, <italic>P = </italic>0.01) but not after adjustment for age, race and sex (<italic>P = </italic>0.25 for Framingham risk score, <italic>P = </italic>0.33 for coronary artery calcium score) (<xref ref-type="table" rid="table2-0961203312462756">Table 2</xref>).</p>
<p>FFAs were positively correlated with the endothelial activation markers, E-selectin and ICAM-1 (rho = 0.33, rho = 0.35 respectively, both <italic>P &lt; </italic>0.001). The association remained significant after adjustment for age, race and sex (both <italic>P = </italic>0.001) (<xref ref-type="table" rid="table2-0961203312462756">Table 2</xref>), and with additional adjustment for BMI (<italic>P = </italic>0.001 for E-selectin, <italic>P = </italic>0.01 for ICAM-1). This association persisted after further adjustment for IL-6 (<italic>P = </italic>0.003 for E-selectin, <italic>P = </italic>0.02 for ICAM-1) and TNF-α (<italic>P = </italic>0.01 for E-selectin, <italic>P = </italic>0.03 for ICAM-I). FFAs were not associated with VCAM-1 in univariate and adjusted analysis.</p>
</sec>
<sec id="sec11-0961203312462756"><title>FFAs and medications</title>
<p>Concentrations of FFAs did not differ significantly among patients with SLE currently using or not using methotrexate, hydroxychloroquine, prednisone, azathioprine or mycophenolate mofetil (all adjusted <italic>P</italic> values &gt; 0.05) (<xref ref-type="table" rid="table3-0961203312462756">Table 3</xref>). Similarly, statin use was not associated with concentrations of FFAs (<italic>P</italic> adjusted = 0.65).
<table-wrap id="table3-0961203312462756" position="float"><label>Table 3</label><caption><p>Effect of medication use on free fatty acids in patients with systemic lupus erythematosus</p></caption>
<graphic alternate-form-of="table3-0961203312462756" xlink:href="10.1177_0961203312462756-table3.tif"/>
<table frame="hsides"><thead align="left">
<tr><th align="center" colspan="5">FFAs median<hr/></th>
</tr>
<tr><th>Medication</th>
<th>Current use</th>
<th>No current use</th>
<th><italic>P</italic> value</th>
<th>Adjusted<sup><xref ref-type="table-fn" rid="table-fn12-0961203312462756">a</xref></sup> <italic>P</italic> value</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Methotrexate</td>
<td>0.54 mmol/l [0.38–0.59]</td>
<td>0.56 mmol/l [0.37–0.72]</td>
<td>0.58</td>
<td>0.55</td>
</tr>
<tr>
<td>Hydroxychloroquine</td>
<td>0.58 mmol/l [0.37–0.73]</td>
<td>0.53 mmol/l [0.40–0.66]</td>
<td>0.55</td>
<td>0.60</td>
</tr>
<tr>
<td>Prednisone</td>
<td>0.55 mmol/l [0.37–0.72]</td>
<td>0.55 mmol/l [0.37–0.69]</td>
<td>0.73</td>
<td>0.95</td>
</tr>
<tr>
<td>Azathioprine</td>
<td>0.42 mmol/l [0.32–0.56]</td>
<td>0.56 mmol/l [0.38–0.72]</td>
<td>0.07</td>
<td>0.20</td>
</tr>
<tr>
<td>Mycophenolate</td>
<td>0.56 mmol/l [0.49-0.69]</td>
<td>0.55 mmol/l [0.37–0.71]</td>
<td>0.57</td>
<td>0.23</td>
</tr>
<tr>
<td>Statin class</td>
<td>0.51 mmol/l [0.35–0.71]</td>
<td>0.55 mmol/l [0.37–0.71]</td>
<td>0.73</td>
<td>0.65</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn11-0961203312462756"><p>FFAs: Free fatty acids.Data presented as median [interquartile range].</p></fn>
<fn id="table-fn12-0961203312462756"><label>a</label><p>Adjusted for age, race and sex.</p></fn></table-wrap-foot>
</table-wrap></p>
</sec>
</sec>
<sec id="sec12-0961203312462756" sec-type="discussion"><title>Discussion</title>
<p>The major new findings of this study are that FFAs are elevated in patients with SLE, particularly in those with metabolic syndrome, and that these FFAs may contribute to endothelial activation and insulin resistance.</p>
<p>To our knowledge, elevation of FFAs in patients with SLE has not been described. However, it appears that the major contribution to the elevation of FFAs in patients with SLE is related to increased BMI rather than inflammation, contrary to our hypothesis.</p>
<p>Inflammatory cytokines can increase FFAs. Several <italic>in vitro</italic> studies in which IL-6 or TNF-α were added to isolated adipocytes resulted in increased lipolysis.<sup><xref ref-type="bibr" rid="bibr30-0961203312462756">30</xref>,</sup> <sup><xref ref-type="bibr" rid="bibr31-0961203312462756">31</xref></sup> Moreover, infusions of IL-6 or TNF-α in healthy subjects resulted in an acute increase in circulating FFAs. <sup><xref ref-type="bibr" rid="bibr32-0961203312462756">32</xref>,</sup> <sup><xref ref-type="bibr" rid="bibr33-0961203312462756">33</xref></sup> However, these studies examined acute changes. In our study, patients with SLE had chronically increased concentrations of IL-6 and TNF-α and there was no correlation between these cytokines and FFAs. Thus, duration of exposure to inflammatory cytokines may alter their lipolytic effect.</p>
<p>Insulin resistance and FFAs may have a cause and effect relationship. For example, insulin resistance developed when FFAs were increased in healthy subjects through lipid infusion.<sup><xref ref-type="bibr" rid="bibr34-0961203312462756">34</xref></sup> Conversely, insulin sensitivity improved when the concentration of FFAs was decreased in obese patients.<sup><xref ref-type="bibr" rid="bibr35-0961203312462756">35</xref></sup> We found a correlation between FFAs and insulin resistance, as determined by HOMA, as well as with the presence of metabolic syndrome. However, the relationship was lost after statistical adjustment for BMI. Thus, contrary to our hypothesis that inflammation drives lipolysis, the major driving factor of elevated FFAs in SLE was BMI, suggesting that simply the presence of more adipose tissue provided more FFAs. In contrast, we recently reported that FFAs in patients with rheumatoid arthritis are associated with insulin resistance (HOMA) independent of BMI.<sup><xref ref-type="bibr" rid="bibr36-0961203312462756">36</xref></sup> These differences between SLE and rheumatoid arthritis are interesting in that BMI appears to contribute more to insulin resistance in patients with SLE than in those with rheumatoid arthritis.<sup><xref ref-type="bibr" rid="bibr37-0961203312462756">37</xref></sup></p>
<p>FFAs have been linked to atherosclerosis. FFAs were correlated with carotid intima media thickness (IMT) in diabetic patients but not in control subjects.<sup><xref ref-type="bibr" rid="bibr38-0961203312462756">38</xref></sup> Similarly, FFAs and carotid IMT were significantly correlated in renal transplant recipients; a population where increased FFAs, chronic inflammation and insulin resistance are prevalent.<sup><xref ref-type="bibr" rid="bibr39-0961203312462756">39</xref></sup> We found that FFAs were associated with coronary calcium score in patients with SLE but the significance was attenuated after adjustment for age, race and sex.</p>
<p>Although there was no independent association between FFAs and coronary artery calcium score, our findings suggest that FFAs may promote endothelial dysfunction in patients with SLE. The evidence linking FFAs and atherosclerosis is based in part on their known effects on vascular endothelium.<sup><xref ref-type="bibr" rid="bibr40-0961203312462756">40</xref></sup> A transient increase in plasma FFAs within the range seen in obesity and type 2 diabetes mellitus increased circulating ICAM-1, VCAM-1 and E-selectin concentrations between 13% and 35% in healthy subjects.<sup><xref ref-type="bibr" rid="bibr17-0961203312462756">17</xref></sup> ICAM-1 is expressed on endothelial cells and lymphocytes, and its soluble form correlates with a degree of atherosclerosis as determined by carotid artery IMT in hypertensive diabetic patients.<sup><xref ref-type="bibr" rid="bibr41-0961203312462756">41</xref></sup> E-selectin is expressed on activated endothelial cells and is responsible for adhesion and migration of leukocytes;<sup><xref ref-type="bibr" rid="bibr42-0961203312462756">42</xref></sup> its soluble form is an independent predictor of carotid plaque in SLE.<sup><xref ref-type="bibr" rid="bibr43-0961203312462756">43</xref></sup> Therefore, our finding of an independent association between ICAM-1 and E-selectin with FFAs in patients with SLE is of interest.</p>
<p>The limitations of our study include the cross-sectional design that precludes the inference of cause and effect. Also, we did not measure non-calcified coronary atherosclerotic plaque and, thus, cannot exclude the possibility that such plaques are associated with elevated FFAs. Also, we only studied fasting circulating FFAs and not rate of appearance or postprandial concentrations; specific studies to address those responses in patients with SLE and controls would be of interest. The assay used to measure FFAs does not detect oxidized fatty acids. This would also be of interest in future studies.</p>
<p>In conclusion, concentrations of FFAs are higher in patients with SLE than controls, largely due to elevated BMI and not inflammation. FFAs are associated with the presence of insulin resistance and metabolic syndrome. Additionally, FFAs are independently associated with markers of endothelial activation but not with coronary artery calcium.</p>
</sec>
</body>
<back>
<sec id="sec13-0961203312462756"><title>Funding</title>
<p>This work was supported by grants P60 AR056116/AR/NIAMS NIH HHS/United States, R01 HL065082-09/HL/NHLBI NIH HHS/United States, T32 AR059039-02/NIAMS NIH HHS/United States, P60 DK020593/NIDDK NIH HHS/United States.</p>
</sec>
<sec id="sec14-0961203312462756"><title>Conflict of interest statement</title>
<p>The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0961203312462756"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Asanuma</surname><given-names>Y</given-names></name><name><surname>Oeser</surname><given-names>A</given-names></name><name><surname>Shintani</surname><given-names>AK</given-names></name><etal/></person-group>. <article-title>Premature coronary-artery atherosclerosis in systemic lupus erythematosus</article-title>. <source>New Engl J Med</source> <year>2003</year>; <volume>349</volume>: <fpage>2407</fpage>–<lpage>2415</lpage>.</citation></ref>
<ref id="bibr2-0961203312462756"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roman</surname><given-names>MJ</given-names></name><name><surname>Shanker</surname><given-names>BA</given-names></name><name><surname>Davis</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus</article-title>. <source>New Engl J Med</source> <year>2003</year>; <volume>349</volume>: <fpage>2399</fpage>–<lpage>2406</lpage>.</citation></ref>
<ref id="bibr3-0961203312462756"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Esdaile</surname><given-names>JM</given-names></name><name><surname>Abrahamowicz</surname><given-names>M</given-names></name><name><surname>Grodzicky</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>2001</year>; <volume>44</volume>: <fpage>2331</fpage>–<lpage>2337</lpage>.</citation></ref>
<ref id="bibr4-0961203312462756"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>CP</given-names></name><name><surname>Oeser</surname><given-names>A</given-names></name><name><surname>Avalos</surname><given-names>I</given-names></name><name><surname>Raggi</surname><given-names>P</given-names></name><name><surname>Stein</surname><given-names>CM</given-names></name></person-group>. <article-title>Cardiovascular risk scores and the presence of subclinical coronary artery atherosclerosis in women with systemic lupus erythematosus</article-title>. <source>Lupus</source> <year>2006</year>; <volume>15</volume>: <fpage>562</fpage>–<lpage>569</lpage>.</citation></ref>
<ref id="bibr5-0961203312462756"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>CP</given-names></name><name><surname>Avalos</surname><given-names>I</given-names></name><name><surname>Oeser</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors</article-title>. <source>Ann Rheum Dis</source> <year>2007</year>; <volume>66</volume>: <fpage>208</fpage>–<lpage>214</lpage>.</citation></ref>
<ref id="bibr6-0961203312462756"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hunt</surname><given-names>KJ</given-names></name><name><surname>Resendez</surname><given-names>RG</given-names></name><name><surname>Williams</surname><given-names>K</given-names></name><name><surname>Haffner</surname><given-names>SM</given-names></name><name><surname>Stern</surname><given-names>MP</given-names></name></person-group>. <article-title>National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study</article-title>. <source>Circulation</source> <year>2004</year>; <volume>110</volume>: <fpage>1251</fpage>–<lpage>1257</lpage>.</citation></ref>
<ref id="bibr7-0961203312462756"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boden</surname><given-names>G</given-names></name></person-group>. <article-title>Obesity and free fatty acids</article-title>. <source>Endocrin Metab Clin</source> <year>2008</year>; <volume>37</volume>: <fpage>635</fpage>–<lpage>46, viii–ix</lpage>.</citation></ref>
<ref id="bibr8-0961203312462756"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boden</surname><given-names>G</given-names></name></person-group>. <article-title>Role of fatty acids in the pathogenesis of insulin resistance and NIDDM</article-title>. <source>Diabetes</source> <year>1997</year>; <volume>46</volume>: <fpage>3</fpage>–<lpage>10</lpage>.</citation></ref>
<ref id="bibr9-0961203312462756"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Langin</surname><given-names>D</given-names></name><name><surname>Holm</surname><given-names>C</given-names></name><name><surname>Lafontan</surname><given-names>M</given-names></name></person-group>. <article-title>Adipocyte hormone-sensitive lipase: a major regulator of lipid metabolism</article-title>. <source>P Nutr Soc</source> <year>1996</year>; <volume>55</volume>: <fpage>93</fpage>–<lpage>109</lpage>.</citation></ref>
<ref id="bibr10-0961203312462756"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boden</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name></person-group>. <article-title>Effects of fat on glucose uptake and utilization in patients with non-insulin-dependent diabetes</article-title>. <source>J Clin Invest</source> <year>1995</year>; <volume>96</volume>: <fpage>1261</fpage>–<lpage>1268</lpage>.</citation></ref>
<ref id="bibr11-0961203312462756"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dresner</surname><given-names>A</given-names></name><name><surname>Laurent</surname><given-names>D</given-names></name><name><surname>Marcucci</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity</article-title>. <source>J Clin Invest</source> <year>1999</year>; <volume>103</volume>: <fpage>253</fpage>–<lpage>259</lpage>.</citation></ref>
<ref id="bibr12-0961203312462756"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>MD</given-names></name><name><surname>Haymond</surname><given-names>MW</given-names></name><name><surname>Rizza</surname><given-names>RA</given-names></name><name><surname>Cryer</surname><given-names>PE</given-names></name><name><surname>Miles</surname><given-names>JM</given-names></name></person-group>. <article-title>Influence of body fat distribution on free fatty acid metabolism in obesity</article-title>. <source>J Clin Invest</source> <year>1989</year>; <volume>83</volume>: <fpage>1168</fpage>–<lpage>1173</lpage>.</citation></ref>
<ref id="bibr13-0961203312462756"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>A</given-names></name><name><surname>Dobias</surname><given-names>SB</given-names></name><name><surname>Walters</surname><given-names>DJ</given-names></name><name><surname>Brasier</surname><given-names>AR</given-names></name></person-group>. <article-title>Tumor necrosis factor increases the rate of lipolysis in primary cultures of adipocytes without altering levels of hormone-sensitive lipase</article-title>. <source>Endocrinology</source> <year>1994</year>; <volume>134</volume>: <fpage>2581</fpage>–<lpage>2588</lpage>.</citation></ref>
<ref id="bibr14-0961203312462756"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Souza</surname><given-names>SC</given-names></name><name><surname>Yamamoto</surname><given-names>MT</given-names></name><name><surname>Franciosa</surname><given-names>MD</given-names></name><name><surname>Lien</surname><given-names>P</given-names></name><name><surname>Greenberg</surname><given-names>AS</given-names></name></person-group>. <article-title>BRL 49 653 blocks the lipolytic actions of tumor necrosis factor-alpha: a potential new insulin-sensitizing mechanism for thiazolidinediones</article-title>. <source>Diabetes</source> <year>1998</year>; <volume>47</volume>: <fpage>691</fpage>–<lpage>695</lpage>.</citation></ref>
<ref id="bibr15-0961203312462756"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boden</surname><given-names>G</given-names></name><name><surname>She</surname><given-names>P</given-names></name><name><surname>Mozzoli</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-kappaB pathway in rat liver</article-title>. <source>Diabetes</source> <year>2005</year>; <volume>54</volume>: <fpage>3458</fpage>–<lpage>3465</lpage>.</citation></ref>
<ref id="bibr16-0961203312462756"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tripathy</surname><given-names>D</given-names></name><name><surname>Mohanty</surname><given-names>P</given-names></name><name><surname>Dhindsa</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects</article-title>. <source>Diabetes</source> <year>2003</year>; <volume>52</volume>: <fpage>2882</fpage>–<lpage>2887</lpage>.</citation></ref>
<ref id="bibr17-0961203312462756"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mathew</surname><given-names>M</given-names></name><name><surname>Tay</surname><given-names>E</given-names></name><name><surname>Cusi</surname><given-names>K</given-names></name></person-group>. <article-title>Elevated plasma free fatty acids increase cardiovascular risk by inducing plasma biomarkers of endothelial activation, myeloperoxidase and PAI-1 in healthy subjects</article-title>. <source>Cardiovasc Diabetol</source> <year>2010</year>; <volume>9</volume>: <fpage>9</fpage>–<lpage>9</lpage>.</citation></ref>
<ref id="bibr18-0961203312462756"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Inoguchi</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Umeda</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C–dependent activation of NAD(P)H oxidase in cultured vascular cells</article-title>. <source>Diabetes</source> <year>2000</year>; <volume>49</volume>: <fpage>1939</fpage>–<lpage>1945</lpage>.</citation></ref>
<ref id="bibr19-0961203312462756"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chinen</surname><given-names>I</given-names></name><name><surname>Shimabukuro</surname><given-names>M</given-names></name><name><surname>Yamakawa</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Vascular lipotoxicity: endothelial dysfunction via fatty-acid-induced reactive oxygen species overproduction in obese Zucker diabetic fatty rats</article-title>. <source>Endocrinology</source> <year>2007</year>; <volume>148</volume>: <fpage>160</fpage>–<lpage>165</lpage>.</citation></ref>
<ref id="bibr20-0961203312462756"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schachinger</surname><given-names>V</given-names></name><name><surname>Britten</surname><given-names>MB</given-names></name><name><surname>Zeiher</surname><given-names>AM</given-names></name></person-group>. <article-title>Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease</article-title>. <source>Circulation</source> <year>2000</year>; <volume>101</volume>: <fpage>1899</fpage>–<lpage>1906</lpage>.</citation></ref>
<ref id="bibr21-0961203312462756"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Asanuma</surname><given-names>Y</given-names></name><name><surname>Chung</surname><given-names>CP</given-names></name><name><surname>Oeser</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors</article-title>. <source>J Rheum</source> <year>2006</year>; <volume>33</volume>: <fpage>539</fpage>–<lpage>545</lpage>.</citation></ref>
<ref id="bibr22-0961203312462756"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rho</surname><given-names>YH</given-names></name><name><surname>Chung</surname><given-names>CP</given-names></name><name><surname>Oeser</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Novel cardiovascular risk factors in premature coronary atherosclerosis associated with systemic lupus erythematosus</article-title>. <source>J Rheum</source> <year>2008</year>; <volume>35</volume>: <fpage>1789</fpage>–<lpage>1794</lpage>.</citation></ref>
<ref id="bibr23-0961203312462756"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>EM</given-names></name><name><surname>Cohen</surname><given-names>AS</given-names></name><name><surname>Fries</surname><given-names>JF</given-names></name><etal/></person-group>. <article-title>The 1982 revised criteria for the classification of systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>1982</year>; <volume>25</volume>: <fpage>1271</fpage>–<lpage>1277</lpage>.</citation></ref>
<ref id="bibr24-0961203312462756"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bombardier</surname><given-names>C</given-names></name><name><surname>Gladman</surname><given-names>DD</given-names></name><name><surname>Urowitz</surname><given-names>MB</given-names></name><name><surname>Caron</surname><given-names>D</given-names></name><name><surname>Chang</surname><given-names>CH</given-names></name></person-group>. <article-title>Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE</article-title>. <source>Arthritis Rheum</source> <year>1992</year>; <volume>35</volume>: <fpage>630</fpage>–<lpage>640</lpage>.</citation></ref>
<ref id="bibr25-0961203312462756"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gladman</surname><given-names>D</given-names></name><name><surname>Ginzler</surname><given-names>E</given-names></name><name><surname>Goldsmith</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>1996</year>; <volume>39</volume>: <fpage>363</fpage>–<lpage>369</lpage>.</citation></ref>
<ref id="bibr26-0961203312462756"><label>26</label><citation citation-type="journal"><collab>Third Report of the National Cholesterol Education Program (NCEP)</collab>. <article-title>Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report</article-title>. <source>Circulation</source> <year>2002</year>; <volume>106</volume>: <fpage>3143</fpage>–<lpage>3421</lpage>.</citation></ref>
<ref id="bibr27-0961203312462756"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matthews</surname><given-names>DR</given-names></name><name><surname>Hosker</surname><given-names>JP</given-names></name><name><surname>Rudenski</surname><given-names>AS</given-names></name><name><surname>Naylor</surname><given-names>BA</given-names></name><name><surname>Treacher</surname><given-names>DF</given-names></name><name><surname>Turner</surname><given-names>RC</given-names></name></person-group>. <article-title>Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man</article-title>. <source>Diabetologia</source> <year>1985</year>; <volume>28</volume>: <fpage>412</fpage>–<lpage>419</lpage>.</citation></ref>
<ref id="bibr28-0961203312462756"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reilly</surname><given-names>MP</given-names></name><name><surname>Wolfe</surname><given-names>ML</given-names></name><name><surname>Rhodes</surname><given-names>T</given-names></name><name><surname>Girman</surname><given-names>C</given-names></name><name><surname>Mehta</surname><given-names>N</given-names></name><name><surname>Rader</surname><given-names>DJ</given-names></name></person-group>. <article-title>Measures of insulin resistance add incremental value to the clinical diagnosis of metabolic syndrome in association with coronary atherosclerosis</article-title>. <source>Circulation</source> <year>2004</year>; <volume>110</volume>: <fpage>803</fpage>–<lpage>809</lpage>.</citation></ref>
<ref id="bibr29-0961203312462756"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Agatston</surname><given-names>AS</given-names></name><name><surname>Janowitz</surname><given-names>WR</given-names></name><name><surname>Hildner</surname><given-names>FJ</given-names></name><name><surname>Zusmer</surname><given-names>NR</given-names></name><name><surname>Viamonte</surname><given-names>M</given-names></name><name><surname>Jr, Detrano</surname><given-names>R</given-names></name></person-group>. <article-title>Quantification of coronary artery calcium using ultrafast computed tomography</article-title>. <source>J Am Coll Cardiol</source> <year>1990</year>; <volume>15</volume>: <fpage>827</fpage>–<lpage>832</lpage>.</citation></ref>
<ref id="bibr30-0961203312462756"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kawakami</surname><given-names>M</given-names></name><name><surname>Murase</surname><given-names>T</given-names></name><name><surname>Ogawa</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Human recombinant TNF suppresses lipoprotein lipase activity and stimulates lipolysis in 3T3-L1 cells</article-title>. <source>J Biochem</source> <year>1987</year>; <volume>101</volume>: <fpage>331</fpage>–<lpage>338</lpage>.</citation></ref>
<ref id="bibr31-0961203312462756"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mattacks</surname><given-names>CA</given-names></name><name><surname>Pond</surname><given-names>CM</given-names></name></person-group>. <article-title>Interactions of noradrenalin and tumour necrosis factor alpha, interleukin 4 and interleukin 6 in the control of lipolysis from adipocytes around lymph nodes</article-title>. <source>Cytokine</source> <year>1999</year>; <volume>11</volume>: <fpage>334</fpage>–<lpage>346</lpage>.</citation></ref>
<ref id="bibr32-0961203312462756"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van der Poll</surname><given-names>T</given-names></name><name><surname>Romijn</surname><given-names>JA</given-names></name><name><surname>Wiersinga</surname><given-names>WM</given-names></name><name><surname>Sauerwein</surname><given-names>HP</given-names></name></person-group>. <article-title>Tumor necrosis factor: a putative mediator of the sick euthyroid syndrome in man</article-title>. <source>J Clin Endocr Metab</source> <year>1990</year>; <volume>71</volume>: <fpage>1567</fpage>–<lpage>1572</lpage>.</citation></ref>
<ref id="bibr33-0961203312462756"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Hall</surname><given-names>G</given-names></name><name><surname>Steensberg</surname><given-names>A</given-names></name><name><surname>Sacchetti</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Interleukin-6 stimulates lipolysis and fat oxidation in humans</article-title>. <source>J Clin Endocr Metab</source> <year>2003</year>; <volume>88</volume>: <fpage>3005</fpage>–<lpage>3010</lpage>.</citation></ref>
<ref id="bibr34-0961203312462756"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gomez</surname><given-names>F</given-names></name><name><surname>Jequier</surname><given-names>E</given-names></name><name><surname>Chabot</surname><given-names>V</given-names></name><name><surname>Buber</surname><given-names>V</given-names></name><name><surname>Felber</surname><given-names>JP</given-names></name></person-group>. <article-title>Carbohydrate and lipid oxidation in normal human subjects: its influence on glucose tolerance and insulin response to glucose</article-title>. <source>Metabolism</source> <year>1972</year>; <volume>21</volume>: <fpage>381</fpage>–<lpage>391</lpage>.</citation></ref>
<ref id="bibr35-0961203312462756"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Santomauro</surname><given-names>AT</given-names></name><name><surname>Boden</surname><given-names>G</given-names></name><name><surname>Silva</surname><given-names>ME</given-names></name><etal/></person-group>. <article-title>Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects</article-title>. <source>Diabetes</source> <year>1999</year>; <volume>48</volume>: <fpage>1836</fpage>–<lpage>1841</lpage>.</citation></ref>
<ref id="bibr36-0961203312462756"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ormseth</surname><given-names>MJ</given-names></name><name><surname>Swift</surname><given-names>LL</given-names></name><name><surname>Fazio</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Free fatty acids are associated with insulin resistance but not coronary artery atherosclerosis in rheumatoid arthritis</article-title>. <source>Atherosclerosis</source> <year>2011</year>; <volume>219</volume>: <fpage>869</fpage>–<lpage>874</lpage>.</citation></ref>
<ref id="bibr37-0961203312462756"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>CP</given-names></name><name><surname>Oeser</surname><given-names>A</given-names></name><name><surname>Solus</surname><given-names>JF</given-names></name><etal/></person-group>. <article-title>Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms</article-title>. <source>Arthritis Rheum</source> <year>2008</year>; <volume>58</volume>: <fpage>2105</fpage>–<lpage>2112</lpage>.</citation></ref>
<ref id="bibr38-0961203312462756"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Taniguchi</surname><given-names>A</given-names></name><name><surname>Nakai</surname><given-names>Y</given-names></name><name><surname>Fukushima</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Ultrasonographically assessed carotid atherosclerosis in Japanese type 2 diabetic patients: Role of nonesterified fatty acids</article-title>. <source>Metabolism</source> <year>2002</year>; <volume>51</volume>: <fpage>539</fpage>–<lpage>543</lpage>.</citation></ref>
<ref id="bibr39-0961203312462756"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Armstrong</surname><given-names>KA</given-names></name><name><surname>Hiremagalur</surname><given-names>B</given-names></name><name><surname>Haluska</surname><given-names>BA</given-names></name><etal/></person-group>. <article-title>Free fatty acids are associated with obesity, insulin resistance, and atherosclerosis in renal transplant recipients</article-title>. <source>Transplantation</source> <year>2005</year>; <volume>80</volume>: <fpage>937</fpage>–<lpage>944</lpage>.</citation></ref>
<ref id="bibr40-0961203312462756"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Steinberg</surname><given-names>HO</given-names></name><name><surname>Baron</surname><given-names>AD</given-names></name></person-group>. <article-title>Vascular function, insulin resistance and fatty acids</article-title>. <source>Diabetologia</source> <year>2002</year>; <volume>45</volume>: <fpage>623</fpage>–<lpage>634</lpage>.</citation></ref>
<ref id="bibr41-0961203312462756"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rubio-Guerra</surname><given-names>AF</given-names></name><name><surname>Vargas-Robles</surname><given-names>H</given-names></name><name><surname>Serrano</surname><given-names>AM</given-names></name><name><surname>Vargas-Ayala</surname><given-names>G</given-names></name><name><surname>Rodriguez-Lopez</surname><given-names>L</given-names></name><name><surname>Escalante-Acosta</surname><given-names>BA</given-names></name></person-group>. <article-title>Correlation between the levels of circulating adhesion molecules and atherosclerosis in hypertensive type-2 diabetic patients</article-title>. <source>Clin Exp Hypertens</source> <year>2010</year>; <volume>32</volume>: <fpage>308</fpage>–<lpage>310</lpage>.</citation></ref>
<ref id="bibr42-0961203312462756"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Krieglstein</surname><given-names>CF</given-names></name><name><surname>Granger</surname><given-names>DN</given-names></name></person-group>. <article-title>Adhesion molecules and their role in vascular disease</article-title>. <source>Am J Hypertens</source> <year>2001</year>; <volume>14</volume>: <fpage>44S</fpage>–<lpage>54S</lpage>.</citation></ref>
<ref id="bibr43-0961203312462756"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reynolds</surname><given-names>HR</given-names></name><name><surname>Buyon</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Association of plasma soluble E-selectin and adiponectin with carotid plaque in patients with systemic lupus erythematosus</article-title>. <source>Atherosclerosis</source> <year>2010</year>; <volume>210</volume>: <fpage>569</fpage>–<lpage>574</lpage>.</citation></ref>
</ref-list>
</back>
</article>